Founded in 1994, Ovarian Cancer Research Fund (OCRF) awards grants to researchers working to better understand, identify, treat, and ultimately cure ovarian cancer. OCRF is the oldest and largest U.S. charity funding ovarian cancer research–only two government organizations, National Cancer Institute and Department of Defense, award more. Without sufficient grant support, researchers might otherwise turn their attention to other, better funded diseases. OCRF funding effectively enhances the breadth of the research enterprise in this nation directed specifically to ovarian cancer research.
OCRF has invested over $65 million in ovarian cancer research with 237 grants to top scientists at nearly 70 leading medical centers. Eighty-seven percent (87%) of every dollar raised supports OCRF programs. OCRF grantees are developing innovative strategies for early detection; exploring the genetics that increase risk; determining the underlying molecular biology; identifying new and better treatment targets; and deciphering how and why ovarian cancer spreads, and how to stop it. And all OCRF research grants are approved by our world-class Scientific Advisory Committee comprised of leaders in the field, thus ensuring the highest caliber of selections.
In 2012, OCRF launched a national support program, Woman to Woman, for women undergoing treatment for gynecologic cancer. This unique program, originally founded at Mount Sinai Medical Center in Manhattan, pairs women who have undergone treatment with women who are currently going through it. With the support of our longtime partner, QVC, sites have been established at 16 medical institutions.
With your support, OCRF continues to take the lead in funding the best and most promising ovarian cancer research in our quest to end this terrible disease.